Search Results
Department of Urology Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK
Dame Roma Mitchell Cancer Research Laboratories Faculty of Health Sciences, School of Medicine, The University of Adelaide, Level 4, Hanson Institute Building, DX Number 650 801, Adelaide, South Australia 5000, Australia
Department of Oncology University of Cambridge, Cambridge CB2 2QQ, UK
Cancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK
Department of Urology Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK
Dame Roma Mitchell Cancer Research Laboratories Faculty of Health Sciences, School of Medicine, The University of Adelaide, Level 4, Hanson Institute Building, DX Number 650 801, Adelaide, South Australia 5000, Australia
Department of Oncology University of Cambridge, Cambridge CB2 2QQ, UK
Search for other papers by Adam W Nelson in
Google Scholar
PubMed
Department of Urology Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK
Dame Roma Mitchell Cancer Research Laboratories Faculty of Health Sciences, School of Medicine, The University of Adelaide, Level 4, Hanson Institute Building, DX Number 650 801, Adelaide, South Australia 5000, Australia
Department of Oncology University of Cambridge, Cambridge CB2 2QQ, UK
Cancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK
Department of Urology Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK
Dame Roma Mitchell Cancer Research Laboratories Faculty of Health Sciences, School of Medicine, The University of Adelaide, Level 4, Hanson Institute Building, DX Number 650 801, Adelaide, South Australia 5000, Australia
Department of Oncology University of Cambridge, Cambridge CB2 2QQ, UK
Search for other papers by Wayne D Tilley in
Google Scholar
PubMed
Department of Urology Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK
Dame Roma Mitchell Cancer Research Laboratories Faculty of Health Sciences, School of Medicine, The University of Adelaide, Level 4, Hanson Institute Building, DX Number 650 801, Adelaide, South Australia 5000, Australia
Department of Oncology University of Cambridge, Cambridge CB2 2QQ, UK
Cancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK
Department of Urology Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK
Dame Roma Mitchell Cancer Research Laboratories Faculty of Health Sciences, School of Medicine, The University of Adelaide, Level 4, Hanson Institute Building, DX Number 650 801, Adelaide, South Australia 5000, Australia
Department of Oncology University of Cambridge, Cambridge CB2 2QQ, UK
Cancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK
Department of Urology Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK
Dame Roma Mitchell Cancer Research Laboratories Faculty of Health Sciences, School of Medicine, The University of Adelaide, Level 4, Hanson Institute Building, DX Number 650 801, Adelaide, South Australia 5000, Australia
Department of Oncology University of Cambridge, Cambridge CB2 2QQ, UK
Search for other papers by David E Neal in
Google Scholar
PubMed
Department of Urology Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK
Dame Roma Mitchell Cancer Research Laboratories Faculty of Health Sciences, School of Medicine, The University of Adelaide, Level 4, Hanson Institute Building, DX Number 650 801, Adelaide, South Australia 5000, Australia
Department of Oncology University of Cambridge, Cambridge CB2 2QQ, UK
Cancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK
Department of Urology Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK
Dame Roma Mitchell Cancer Research Laboratories Faculty of Health Sciences, School of Medicine, The University of Adelaide, Level 4, Hanson Institute Building, DX Number 650 801, Adelaide, South Australia 5000, Australia
Department of Oncology University of Cambridge, Cambridge CB2 2QQ, UK
Search for other papers by Jason S Carroll in
Google Scholar
PubMed
Introduction Prostate cancer is the commonest, non-cutaneous cancer in men, affecting 214 per 1000 European men. It is the second commonest cause of cancer death, accounting for 15% of all male cancers in developed countries ( Heidenreich et al
Turku Center for Disease Modeling (TCDM), Institute of Biomedicine, University of Turku, Turku, Finland
Search for other papers by Matias Knuuttila in
Google Scholar
PubMed
Search for other papers by Arfa Mehmood in
Google Scholar
PubMed
Turku Center for Disease Modeling (TCDM), Institute of Biomedicine, University of Turku, Turku, Finland
Search for other papers by Jenni Mäki-Jouppila in
Google Scholar
PubMed
Search for other papers by Henrik Ryberg in
Google Scholar
PubMed
Search for other papers by Pekka Taimen in
Google Scholar
PubMed
Search for other papers by Juha Knaapila in
Google Scholar
PubMed
Search for other papers by Otto Ettala in
Google Scholar
PubMed
Search for other papers by Peter J Boström in
Google Scholar
PubMed
Search for other papers by Claes Ohlsson in
Google Scholar
PubMed
Search for other papers by Mikko S Venäläinen in
Google Scholar
PubMed
Search for other papers by Asta Laiho in
Google Scholar
PubMed
Search for other papers by Laura L Elo in
Google Scholar
PubMed
Turku Center for Disease Modeling (TCDM), Institute of Biomedicine, University of Turku, Turku, Finland
Search for other papers by Petra Sipilä in
Google Scholar
PubMed
Functional Foods Forum, University of Turku, Turku, Finland
Search for other papers by Sari I Mäkelä in
Google Scholar
PubMed
Turku Center for Disease Modeling (TCDM), Institute of Biomedicine, University of Turku, Turku, Finland
Center for Bone and Arthitis Research, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Search for other papers by Matti Poutanen in
Google Scholar
PubMed
Introduction Androgens play a crucial role in the normal development and growth of the prostate and the growth of prostate cancer. The prostate tissue is known for the local biosynthesis of dihydrotestosterone (DHT), which is the principal
Search for other papers by Joanna M Day in
Google Scholar
PubMed
Search for other papers by Paul A Foster in
Google Scholar
PubMed
Search for other papers by Helena J Tutill in
Google Scholar
PubMed
Search for other papers by Fabien Schmidlin in
Google Scholar
PubMed
Search for other papers by Christopher M Sharland in
Google Scholar
PubMed
Search for other papers by Jonathan D Hargrave in
Google Scholar
PubMed
Search for other papers by Nigel Vicker in
Google Scholar
PubMed
Search for other papers by Barry V L Potter in
Google Scholar
PubMed
Search for other papers by Michael J Reed in
Google Scholar
PubMed
Search for other papers by Atul Purohit in
Google Scholar
PubMed
Introduction Treatment of hormone-dependent prostate cancer by androgen ablation is usually initially successful, reducing primary tumour burden and increasing 5-year survival rates. Currently, androgen ablation is achieved using orchidectomy
Search for other papers by Luke A Selth in
Google Scholar
PubMed
Search for other papers by Wayne D Tilley in
Google Scholar
PubMed
Search for other papers by Lisa M Butler in
Google Scholar
PubMed
in prostate cancer (PCa), thyroid cancer, neuroblastoma, and glioblastoma but acts as a tumor suppressor in ovarian and breast cancer (for review, see Cortez et al . (2011) ). Such dichotomy in respect to miRNA function in cancer is not uncommon and
Search for other papers by T M Murphy in
Google Scholar
PubMed
Search for other papers by A S Perry in
Google Scholar
PubMed
Search for other papers by M Lawler in
Google Scholar
PubMed
Introduction Prostate cancer represents a global public health problem. Worldwide, it is the second most common noncutaneous cancer in men, accounting for ∼10% of male cancers ( Parkin et al . 2005 ). Prostate cancer is the second leading cause of
Search for other papers by Renea A Taylor in
Google Scholar
PubMed
Search for other papers by Roxanne Toivanen in
Google Scholar
PubMed
Search for other papers by Gail P Risbridger in
Google Scholar
PubMed
Introduction Prostate cancer is a major cause of morbidity and mortality in men around the world, being the most common solid tumor. In America, ∼6 out of every 50 men over the age of 50 will be diagnosed with prostate cancer in his lifetime. In
Search for other papers by Suresh Veeramani in
Google Scholar
PubMed
Search for other papers by Ta-Chun Yuan in
Google Scholar
PubMed
Search for other papers by Siu-Ju Chen in
Google Scholar
PubMed
Search for other papers by Fen-Fen Lin in
Google Scholar
PubMed
Search for other papers by Juliette E Petersen in
Google Scholar
PubMed
Search for other papers by Syed Shaheduzzaman in
Google Scholar
PubMed
Search for other papers by Shiv Srivastava in
Google Scholar
PubMed
Search for other papers by Richard G MacDonald in
Google Scholar
PubMed
Search for other papers by Ming-Fong Lin in
Google Scholar
PubMed
PAcP is a 100 kDa glycoprotein containing two subunits of approximately 50 kDa each. In the mid 1930s, Gutman and his colleagues made the noteworthy observation that the activity of PAcP is increased in the circulation of patients with prostate cancer
Institute of Health and Biomedical Innovation, Vancouver Prostate Centre, Departments of Medicine and Oncology, Australian Prostate Cancer Research Centre – Queensland, Princess Alexandra Hospital, Queensland University of Technology, Level 1, Building 1, 199 Ipswich Road, Brisbane, Queensland 4102, Australia
Search for other papers by Amy A Lubik in
Google Scholar
PubMed
Search for other papers by Jennifer H Gunter in
Google Scholar
PubMed
Search for other papers by Brett G Hollier in
Google Scholar
PubMed
Search for other papers by Susan Ettinger in
Google Scholar
PubMed
Search for other papers by Ladan Fazli in
Google Scholar
PubMed
Search for other papers by Nataly Stylianou in
Google Scholar
PubMed
Search for other papers by Stephen C Hendy in
Google Scholar
PubMed
Search for other papers by Hans H Adomat in
Google Scholar
PubMed
Search for other papers by Martin E Gleave in
Google Scholar
PubMed
Search for other papers by Michael Pollak in
Google Scholar
PubMed
Search for other papers by Adrian Herington in
Google Scholar
PubMed
Institute of Health and Biomedical Innovation, Vancouver Prostate Centre, Departments of Medicine and Oncology, Australian Prostate Cancer Research Centre – Queensland, Princess Alexandra Hospital, Queensland University of Technology, Level 1, Building 1, 199 Ipswich Road, Brisbane, Queensland 4102, Australia
Search for other papers by Colleen C Nelson in
Google Scholar
PubMed
factors insulin and IGF1 have been implicated in prostate cancer (PC) progression ( Pollak 2008 a , Lubik et al . 2011 ); however, the role of IGF2 is less well explored. IGF2 expression is elevated in ovarian, colorectal and breast cancer associated
Search for other papers by Tanya K Day in
Google Scholar
PubMed
Dame Roma Mitchell Cancer Research Laboratories, School of Paediatrics and Reproductive Health, School of Agriculture, Discipline of Medicine, Hanson Institute, Adelaide Prostate Cancer Research Centre, The University of Adelaide, Adelaide, South Australia, Australia
Search for other papers by Tina Bianco-Miotto in
Google Scholar
PubMed
Introduction Numerous diseases are associated with abnormal hormonal regulation including breast and prostate cancers. Breast cancer is a heterogeneous disease that can be classified in many ways. The most primary classification is by hormone
Department of Cancer Prevention Institute of Cancer Research
Department of Urology Oslo University Hospital, N-0424 Oslo, Norway
Search for other papers by Stefan J Barfeld in
Google Scholar
PubMed
Department of Cancer Prevention Institute of Cancer Research
Department of Urology Oslo University Hospital, N-0424 Oslo, Norway
Search for other papers by Harri M Itkonen in
Google Scholar
PubMed
Department of Cancer Prevention Institute of Cancer Research
Department of Urology Oslo University Hospital, N-0424 Oslo, Norway
Search for other papers by Alfonso Urbanucci in
Google Scholar
PubMed
Department of Cancer Prevention Institute of Cancer Research
Department of Urology Oslo University Hospital, N-0424 Oslo, Norway
Prostate Cancer Research Group Centre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership, University of Oslo and Oslo University Hospital, N-0318 Oslo, Norway
Department of Cancer Prevention Institute of Cancer Research
Department of Urology Oslo University Hospital, N-0424 Oslo, Norway
Prostate Cancer Research Group Centre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership, University of Oslo and Oslo University Hospital, N-0318 Oslo, Norway
Department of Cancer Prevention Institute of Cancer Research
Department of Urology Oslo University Hospital, N-0424 Oslo, Norway
Search for other papers by Ian G Mills in
Google Scholar
PubMed
) ( DeBerardinis et al . 2008 ). It is therefore not surprising that metabolic adaptations have been reported in various human cancers ( Hsu & Sabatini 2008 ). Metabolic status of the prostate gland and cancer predisposition The prostate gland is principally